Anti-tumor effect of 125I-UdR in combination with Egr-1 promoter-based IFNγ gene therapy in vivo
- 122 Downloads
Although 125I-UdR treatment of malignant tumors in animal models and patients has achieved a certain effect, the short half-life of 125I-UdR in vivo and its cellular uptake only in S phase of the cell cycle are limiting factors with regard to tumor eradication, and therefore its combination with other applications is a promising strategy in cancer therapy. In this study, we show that 125I-UdR radionuclide therapy in combination with Egr-1 promoter-based IFNγ gene therapy is more effective than 125I-UdR therapy alone in suppressing tumor growth and extending survival duration in mice bearing H22 hepatomas. Combined therapy could significantly inhibit cell proliferation and tumor angiogenesis, induce apoptosis and enhance cytotoxic activities of splenic CTL of the mice. Our results suggest that 125I-UdR in combination with Egr-1 promoter-based IFNγ gene therapy may provide novel approaches for cancer treatment.
KeywordsProliferate Cell Nuclear Antigen KeyGen Biotech Tumor Inhibition Rate Gene Therapy Group
The authors thank Dr. L. Sun (School of Radiological Medicine and Public Health, Soochow University) for valuable advice on this manuscript. This work was supported by the National Natural Science Foundation of China (No. 30600160) and Program for Changjiang Scholars and Innovative Research Team in University (IRT0849). The authors declare that they have no conflict of interest.
- Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI (1991) 5-[123I]iodo-2’-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 21:1541–1551Google Scholar
- Buchegger F, Adamer F, Schaffland AO, Kosinski M, Grannavel C, Dupertuis YM, de Tribolet N, Mach JP, Delaloye AB (2004) Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. Int J Cancer 110:145–149CrossRefGoogle Scholar
- Horton MR, McKee CM, Bao C, Liao F, Farber JM, Hodge-DuFour J, Puré E, Oliver BL, Wright TM, Noble PW (1998) Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemikines mig and interferon-inducible protein-10 in mouse macrophages. J Biol Chem 273:35088–35094CrossRefGoogle Scholar
- Kassis AI (2003) Cancer therapy with auger electrons: are we almost there? J Nucl Med 44:1479–1481Google Scholar
- Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC (2004) Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 45:1224–1232Google Scholar
- Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T (1998) Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 9:1409–1417CrossRefGoogle Scholar
- Semnani ES, Wang K, Adelstein SJ, Kassis AI (2005) 5-[123I/125I]Iodo-2’-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting. J Nucl Med 46:800–806Google Scholar
- Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538–546Google Scholar
- Sukhatme VP (1990) Early transcriptional events in cell growth: the Egr family. J Am Soc Nephrol 1:859–866Google Scholar
- Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, Kufe DW (1994) Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 54:4266–4269Google Scholar
- Yang W, Li XY (2005) Anti-tumor effect of pEgr-IFNγ-Endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism. Chin Med J 118:296–301Google Scholar